Death, destruction, and the proteasome

New England Journal of Medicine

Volumn 351, Issue 4, 2004, Pages 393-394

  Tansey, William Patrick ^a  

^a Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; BORTEZOMIB; CASPASE 9; CYTOCHROME C; PROTEASOME; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; UBIQUITIN;

ACETYLATION; APOPTOSIS; ARTICLE; CANCER; ENZYME SPECIFICITY; HUMAN; INFLAMMATION; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; UBIQUITINATION;

APOPTOSIS; CARRIER PROTEINS; CASPASES; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MITOCHONDRIAL PROTEINS; PEPTIDE HYDROLASES; PROTEASOME ENDOPEPTIDASE COMPLEX; SERINE ENDOPEPTIDASES; UBIQUITIN;

EID: 3242705721     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMcibr041505     Document Type: Article

References (5)

1. Sun XM, Butterworth M, MacFarlane M, Dubiel W, Ciechanover A, Cohen GM. Caspase activation inhibits proteasome function during apoptosis. Mol Cell 2004;14:81-93.
2. Zhang HG, Wang J, Yang X, Hsu HC, Mountz JD. Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene 2004;23: 2009-15.
3. MacFarlane M, Merrison W, Bratton SB, Cohen GM. Proteasome-mediated degradation of Smac during apoptosis: XIAP promotes Smac ubiquitination in vitro. J Biol Chem 2002;277:36611-6.
4. Kane RC, Bross PF, Farrell AT, Pazdur R. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 2003;8:508-13.
5. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071-6.